Recently, overexpression of p110δ is also observed in solid tumors such as GBM, neuroblastoma, breast and prostate cancers, indicating that inhibition of p110δ may also be an attractive option for GBM treatment [23, 29, 30]. This evidence concerns the gene PIK3CD and Familial prostate cancer.